Looking to bolster immune checkpoint R&D, Gilead buys MiroBio as it takes next-gen checkpoint therapy to the clinic
While Gilead dropped disappointing data on its Arcus-partnered CD37 inhibitor Wednesday afternoon, the biopharma is making moves to cushion its immune checkpoint pipeline.
For $405 million, Gilead will buy MiroBio, an Oxford spinout which just a month ago announced its £80 million Series B round. MiroBio chair Eliot Charles had told Endpoints News then that the biotech was looking for a new CEO, but it appears it won’t need to do that anymore.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 147,300+ biopharma pros reading Endpoints daily — and it's free.